Delhivery Hits Record Q1 Growth: CEO Sahil Barua Weighs In
Delhivery Ltd (BOM:543529) reported record-breaking volumes in Q1 2027, achieving a 55% year-over-year growth rate driven by strong D2C demand…
Why Universal Health Services (UHS) Is a Sell Right Now
Universal Health Services (UHS) stock has plummeted 20.7% over the last six months to $168.95, leaving investors to question whether…
3 Stocks Near 52-Week Highs: One to Buy, Two to Avoid
Investors often view stocks trading near 52-week highs as signs of market strength, but momentum can be deceptive. While some…
Supermicro Q4 Earnings: Can AI Momentum Sustain the Stock?
Supermicro (SMCI) is set to release its fourth-quarter financial results after the market closes this Tuesday, a pivotal moment for…
Humanoid Robot Boom: 2 Industrial Stocks to Profit Now
The race to develop humanoid robots is capturing global market attention, but seasoned investors are looking past the manufacturers to…
SpaceX vs. Quantinuum: Which IPO is the Better Buy?
Investors seeking high-growth opportunities in 2026 are weighing the potential of two major market debuts: Quantinuum (NASDAQ: QNT) and Space…
J&J’s OTTAVA FDA Win and Talc Settlement: What’s Next?
Johnson & Johnson (JNJ) is betting its future on a strategic pivot toward innovative medicines and MedTech, aiming to neutralize…
Microvast Q2 Revenue Dips Amid Tariff Costs and Market Shifts
Microvast (NASDAQ:MVST) reported second-quarter revenue of $87.3 million, a 4.5% decline compared to the same period in 2025, driven by…
$100K Startup Loan Dispute: Husband Refuses to Pay Mother-in-Law
An 81-year-old woman is currently entangled in a bitter financial dispute with her son-in-law, who refuses to repay a $100,000…
Intel Shares Slip After Massive $15 Billion Stock Offering
Intel (NASDAQ: INTC) shares tumbled this Monday following the semiconductor giant’s announcement of a $15 billion stock offering aimed at…
Oncocyte Targets 2024 FDA Nod for GraftAssureDx Kidney Test
Oncocyte (NASDAQ:IMDX) is pushing for FDA marketing authorization of its GraftAssureDx kidney-transplant rejection test by the end of 2024, as…
HCG Q1 2027 Earnings: Profitability Surge and Growth Strategy
HealthCare Global Enterprises Ltd (NSE:HCG) reported a robust start to fiscal year 2027, outlining a clear path toward significant EBITDA…